SCHEMBL1129397

SCHEMBL1129397

COc1cc(Br)ccc1Oc1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
L3MBTL1 Q9Y468 5/20 0.48
HPGD P15428 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
RECQL P46063 1/20 0.45
SLC6A2 P23975 4/20 0.44
SLC6A4 P31645 4/20 0.44
SLC6A3 Q01959 4/20 0.44
KCNH2 Q12809 1/20 0.44
TTR P02766 2/20 0.44
DHPS P49366 2/20 0.43
LMNA P02545 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5607372 0.88 CA2 (0.52) MAPTL3MBTL1HPGDCYP1A2SMN1; SMN2
SCHEMBL27451483 0.82 CA1 (0.59) MAPTL3MBTL1HPGDNPC1RAB9A
SCHEMBL1129135 0.81 AR (0.60) MAPTL3MBTL1HPGDNPC1RAB9A
SCHEMBL5606658 0.80 TP53 (0.55) MAPTL3MBTL1HPGDNPC1RAB9A
SCHEMBL263669 0.78 MAPT (0.47) MAPTL3MBTL1HPGDNPC1CYP2C9
SCHEMBL1129837 0.77 TTR (0.58) L3MBTL1NPC1RAB9ASMN1; SMN2SLC6A4
SCHEMBL14861411 0.76 AR (0.71) MAPTL3MBTL1HPGDNPC1RAB9A
SCHEMBL5606856 0.76 ALDH1A1 (0.54) HPGDCYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL3740375 0.76 MAPT (0.46) MAPTL3MBTL1HPGDNPC1CYP2C9
SCHEMBL14649872 0.76 L3MBTL1 (0.57) MAPTL3MBTL1HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 MAPT 726/4885L3MBTL1 4613/4885HPGD 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.